Edwards SAPIEN 3 TAVR Valve Wins Three NMPA Valve-in-Valve Indications in China

The significance here is less the device than the regulatory pathway: NMPA is now sanctioning transcatheter valve-in-valve treatment across three distinct failed-bioprosthesis scenarios, including the mitral position, under heart-team risk scoring. That widens the addressable pool of patients previously steered toward redo surgery and signals Chinese regulators are comfortable with a broader structural-heart indication set. The open question is whether this first-mover labelling advantage holds as rival transcatheter platforms pursue comparable Chinese approvals, and how quickly heart-team scoring becomes the practical gatekeeper for access.